Topics

Phase 3 Trial of Takeda’s Ninlaro as First-Line Maintenance Therapy Met Primary Endpoint in Certain Multiple Myeloma Patients

13:46 EST 7 Nov 2019 | Speciality Pharma Journal

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma

Original Article: Phase 3 Trial of Takeda’s Ninlaro as First-Line Maintenance Therapy Met Primary Endpoint in Certain Multiple Myeloma Patients

NEXT ARTICLE

More From BioPortfolio on "Phase 3 Trial of Takeda’s Ninlaro as First-Line Maintenance Therapy Met Primary Endpoint in Certain Multiple Myeloma Patients"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...